A type of drug given to men with prostate cancer, called GnRH (gonadotropin-releasing hormone) agonists have been linked to a higher risk of developing diabetes, stroke or heart disease, and thus must have new warnings on their labels, said the US Food and Drug Administration (FDA). An ongoing analysis which started in May this year found that men on GnRH agonists had a slightly elevated risk of having a heart attack, becoming diabetic, suffering from a stroke, or sudden death... 
More...
More...